- American City Business Journals•18 hours ago
Gilead Sciences Inc. spent $125 million for a voucher that could speed FDA review of a drug, but one analyst said the seller may have undervalued the asset. Sarepta Therapeutics of Cambridge, Mass., on Tuesday said it sold the so-called priority review voucher to Foster City-based Gilead Sciences Inc. (GILD). Sarepta (SRPT) had received the rare pediatric disease voucher when the Food and Drug Administration approved its Duchenne muscular dystrophy drug, Exondys51, in September.
- Investopedia•21 hours ago
Sarepta sold its Priority Review Voucher for $125 million to Gilead.
- TheStreet.com•21 hours ago
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.
SRPT : Summary for Sarepta Therapeutics, Inc. - Yahoo Finance
Sarepta Therapeutics, Inc. (SRPT)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
|Bid||28.54 x 1000|
|Ask||28.99 x 300|
|Day's Range||28.08 - 29.00|
|52 Week Range||8.00 - 63.73|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-5.45|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|